UniSuper Management Pty Ltd Buys 986 Shares of Amgen Inc. $AMGN

UniSuper Management Pty Ltd raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the 1st quarter, Holdings Channel.com reports. The fund owned 89,784 shares of the medical research company’s stock after purchasing an additional 986 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Amgen were worth $27,972,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Rise Advisors LLC lifted its stake in shares of Amgen by 113.1% in the 1st quarter. Rise Advisors LLC now owns 1,089 shares of the medical research company’s stock worth $339,000 after purchasing an additional 578 shares during the period. Plancorp LLC lifted its stake in shares of Amgen by 1.4% in the 1st quarter. Plancorp LLC now owns 3,072 shares of the medical research company’s stock worth $957,000 after purchasing an additional 43 shares during the period. New England Asset Management Inc. lifted its stake in shares of Amgen by 10.1% in the 1st quarter. New England Asset Management Inc. now owns 21,295 shares of the medical research company’s stock worth $6,634,000 after purchasing an additional 1,950 shares during the period. Nissay Asset Management Corp Japan ADV lifted its stake in shares of Amgen by 9.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 133,412 shares of the medical research company’s stock worth $41,565,000 after purchasing an additional 11,694 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Amgen by 9.7% in the 1st quarter. NewEdge Advisors LLC now owns 75,784 shares of the medical research company’s stock worth $23,611,000 after purchasing an additional 6,685 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.3%

Amgen stock opened at $283.64 on Friday. The firm has a 50 day moving average of $293.85 and a 200 day moving average of $292.60. The firm has a market capitalization of $152.70 billion, a price-to-earnings ratio of 23.19, a P/E/G ratio of 2.46 and a beta of 0.49. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $339.17. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is 77.84%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.76% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Piper Sandler increased their price objective on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective on the stock. UBS Group lowered their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Finally, Bank of America increased their price objective on shares of Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $304.43.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.